Fibrinogen in Liver Transplant Subjects

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions
Liver Transplant Surgery
Interventions
BIOLOGICAL

Cryoprecipitate Intercept Fibrinogen Complex (IFC)

INTERCEPT Fibrinogen Complex is a pathogen-reduced cryoprecipitated fibrinogen complex derived from human plasma. It contains fibrinogen, Factor XIII, and von Willebrand factor to achieve stable clot formation and restore hemostasis1. Recently approved by the US Food and Drug Administration, it is used for the treatment of bleeding associated with fibrinogen deficiency.

BIOLOGICAL

Cryoprecipitate Antihemophilic Factor (AHF)

Cryoprecipitate Antihemophilic Factor (AHF), also known as cryo, is a frozen blood product prepared from blood plasma. It is used for fibrinogen supplementation, particularly for hypofibrinogenemia fibrinogen, anemia associated with bleeding or congenital deficiency.

Trial Locations (3)

15213

UPMC Montefiore Hospital, Pittsburgh

UPMC Presbyterian Hospital, Pittsburgh

45221

University of Cincinnati, Cincinnati

All Listed Sponsors
lead

Ezeldeen Abuelkasem

OTHER